“FDA Sets the Stage for Earlier-Stage Alzheimer’s Treatments,” by Zack’s Equity Research, NASDAQ

Quote: “The FDA has proposed new guidelines, which are aimed at lowering the clinical study goals of Alzheimer’s disease drugs for treating earlier-stage patients who have not yet displayed functional disability or clinical abnormality. This strategy, part of FDA’s ongoing efforts to expand access to safe and effective treatment options for many serious conditions, suggests that the agency may be open to an accelerated approval process for such drugs. FDA’s proposed guidelines came in a week when major disappointments in the field were announced by companies developing drugs to treat this deadly brain disease.”

LTC Comment (from Stephen A. Moses, President, Center for Long-Term Care Reform):

A silver lining on a very dark cloud.

FDA Sets the Stage for Earlier-Stage Alzheimer’s Treatments

#FDA
#Alzheimer’s
#goldencareagent